Connect your AI

PTHS PTHS Xepi Royalty Agreement — Contractual obligation, measurement input

Similar metrics at other companies

XOMAIxinity — Rights Receivable Eir Method Payment Of Sales Based Milestones

$5.66M—

INVAXerava — Percentage Of Royalty Payable On Net Sales

0.6%0.0pp

SCLXScilex Pharma — Royalty Expense

$1.2M+33.3%

HTGCRoyalty Contract — Investment cost

$11.5M-3.4%

XOMAXaciato — Rights Receivable Cost Recovery Method

$21.99M0.0%

OCCRoyalty Revenue Expense

-$6.62K-0.7%

Other financials

Income statement

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation

Market cap$98.22M+75.4%

Enterprise value$95.89M—

P/S3.6×—

Profitability

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Returns & leverage

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:ContractualObligationMeasurementInput.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's xepi royalty agreement — contractual obligation, measurement input.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is PTHS's xepi royalty agreement — contractual obligation, measurement input?: PTHS (PTHS) reported xepi royalty agreement — contractual obligation, measurement input of 95% in Q1 2026.
What does xepi royalty agreement — contractual obligation, measurement input mean?: The primary quantitative data points or assumptions used to calculate the fair value or carrying amount of the Xepi royalty obligation. This input is critical for investors to understand the sensitivity and valuation methodology applied to the company's long-term licensing liabilities.